Clinical trial
DNA Vaccine for Ragweed Allergic Adults
NCT00346086 · Johns Hopkins University, Other · Completed
Key facts
| NCT number | NCT00346086 |
|---|---|
| Title | DNA Vaccine for Ragweed Allergic Adults |
| Official title | A Phase II Observer-blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, Tolerability, and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults (Sponsor's Protocol NRH01) |
| Lead sponsor | Johns Hopkins University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Seasonal Allergic Rhinitis |
| Intervention type | Drug |
| Interventions | AIC (Amb a 1 Immunostimulatory Conjugate) |
| Enrollment | 25 |
| Start date | May 18, 2001 |
| Primary completion | Aug 21, 2001 |
| Completion | Aug 21, 2001 |
| First posted | Jun 29, 2006 |
| Last update posted | Dec 13, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: